Review article · 2025 · Open access

From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery

Tomasz Szostek, Daniel Szulczyk

Drug Discovery Today, 31(1), 104589 · Published 17 December 2025 · DOI 10.1016/j.drudis.2025.104589

Open full textCite this paper

In brief

“From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery” is a 2025 review article by Tomasz Szostek and Daniel Szulczyk, published in Drug Discovery Today. OpenAlex counts 12 citations as of 18 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Drug Discovery Today.

Citations
12
Most cited in
2026 (12)
Field-weighted impact
0.50
References
101
Authors
2

Abstract

Activity cliffs (ACs), defined as near structural neighbors with large potency differences, provide high-value information on structure-activity relationship discontinuities that medicinal chemists have leveraged for years. Yet modern artificial intelligence-based discovery frameworks often smooth this signal, yielding confident but unrealistic proposals. We present a three-layer roadmap that treats ACs as a first-class design feature: representation is tuned to expose AC signal during pretraining and sampling; evaluation focuses on steep regions with early recognition, pair-level retrieval, and calibrated uncertainty under fair, series-aware splits; and de novo generation is steered toward the best candidates. Integrated as a closed, self-improving loop, this framework helps practitioners build AC-aware drug design tools.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Szostek, T., & Szulczyk, D. (2025). From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery. Drug Discovery Today, 31(1), 104589. https://doi.org/10.1016/j.drudis.2025.104589

MLA 9

Szostek, Tomasz, and Daniel Szulczyk. “From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery.” Drug Discovery Today, vol. 31, no. 1, 2025, p. 104589. https://doi.org/10.1016/j.drudis.2025.104589.

Chicago

Szostek, Tomasz and Daniel Szulczyk. 2025. “From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery.” Drug Discovery Today 31 (1): 104589. https://doi.org/10.1016/j.drudis.2025.104589.

Harvard

Szostek, T. and Szulczyk, D. (2025) ‘From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery’, Drug Discovery Today, 31(1), p. 104589. doi:10.1016/j.drudis.2025.104589.

IEEE

T. Szostek and D. Szulczyk, “From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery,” Drug Discovery Today, vol. 31, no. 1, p. 104589, 2025, doi: 10.1016/j.drudis.2025.104589.

BibTeX

@article{szostek2025from,
  title     = {{From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery}},
  author    = {Szostek, Tomasz and Szulczyk, Daniel},
  journal   = {Drug Discovery Today},
  year      = {2025},
  volume    = {31},
  number    = {1},
  pages     = {104589},
  doi       = {10.1016/j.drudis.2025.104589},
  url       = {https://doi.org/10.1016/j.drudis.2025.104589}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • activity cliffs
  • small molecule drug discovery
  • de novo molecule generation
  • uncertainty calibration
  • structure representation

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Szostek, T., & Szulczyk, D. (2025). From obstacle to design advantage: activity cliff aware modeling for small-molecule drug discovery. Drug Discovery Today, 31(1), 104589. https://doi.org/10.1016/j.drudis.2025.104589

How many times has this paper been cited?

12 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Drug Discovery Today: sign in and open the full text from this page.

Who wrote this paper?

Tomasz Szostek, Daniel Szulczyk.

What is the DOI of this paper?

10.1016/j.drudis.2025.104589, permanently at https://doi.org/10.1016/j.drudis.2025.104589. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.